

Special Issue

Eosinophil: Current Status and Future Perspectives

Message from the Guest Editor

This Special Issue invites research articles and reviews that investigate the complex biology of eosinophils, including their activation, migration, and effector functions. It seeks to understand how eosinophils contribute to the resolution of infections, their role in maintaining tissue homeostasis, and their involvement in allergic and inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic disorders together with cancers.

Furthermore, this Special Issue encourages studies that explore the potential of eosinophils as therapeutic targets, particularly in the context of allergic diseases and cancer, where they have been implicated in both tumor suppression and promotion. It also welcomes research on the development of novel diagnostic tools, predictive biomarkers, and therapeutic strategies to modulate eosinophil activity, with the goal of improving clinical outcomes for patients.

Guest Editor

Prof. Dr. Ildiko Horvath

1. National Koranyi Institute for Pulmonology, Budapest, Hungary
2. Department of Pulmonology, University of Debrecen, Debrecen, Hungary

Deadline for manuscript submissions

30 September 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/197896

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).